ClinicalTrials.gg
RecruitingNCT06105645NENUFARUpdated Oct 21, 2026

Contribution of Fast-ripples to the Improvement of the Neurosurgical Management of Drug-refractory Epilepsy

An interventional study of DIXI Medical Microdeep® Micro- Macro Depth electrodes and Standard electrodes in Epilepsy, sponsored by University Hospital, Toulouse. Recruiting at 12 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.
Updated Oct 21, 2026Site recruiting status changedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
440
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Epilepsy by University Hospital, Toulouse — 5 open to participants now, 6 under way, none of them phase 3. Epilepsy · University Hospital, Toulouse.

Started
2024
the only one that year
No phase
6 of 10
3 open now
Registered
8th of 10
by date

Among the 10 studies in Epilepsy by University Hospital, Toulouse, this one is the only one that started in 2024, is one of 6 with no phase, and was the 8th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

5 of the 10 studies in Epilepsy by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Epilepsy by University Hospital, Toulouse, or all of them as a file.
02

Study summary

The main aim of this study is to evaluate the contribution of fast-ripples (FR) information on the neurosurgery management of patients with drug-refractory epilepsy investigated by Stereo-ElectroEncephaloGraphy (SEEG), as measured by freedom from disabling seizures one-year post-surgery.

220 patients (for whom 4-6 usual clinical macro-electrodes will be replaced by hybrid micro-macro electrodes and for whom fast-ripples will be assessed) distributed over 6 centres and 220 control patients(who will undergo an SEEG with the usual electrodes and for whom fast-ripples will not be assessed) distributed over 6 centres. This is a controlled, non-randomized, parallel plan, prospective, multicentre exploratory study.

Read the detailed description

This is a controlled, non-randomized, parallel plan, prospective, multicentre exploratory study. The design of the study relies on two groups of patients benefiting from a SEEG, equivalent in size: one with standard and hybrid electrodes for which fast-ripple information will be available for the neurosurgery decision, the other, who will serve as a control group, with standard electrodes only and for which no information regarding fast-ripples will be provided. For all patients undergoing SEEG, the decisions about eligibility to epilepsy surgery and, if eligible, about the best surgical plan, are taken during a multidisciplinary epilepsy meeting (MEM) within the 4 +/- 2 months following the SEEG. In the group of patients with standard and hybrid electrodes, the procedure as extensively tested previously, is to plan the implantation of the standard electrodes as usually done, and once done, to replace from 4 to 6 standard electrodes with hybrid electrodes. In this group, intracerebral ElectroEncephaloGraphy (EEG) data will be acquired for detection of fast-ripples, during one hour of a rest period for 2 days during the first week of SEEG, as well as during one cycle of night sleep when possible. Fast-ripples(number, localization and characteristics) for all these patients will be analysed by an expert group of neuroscientists based in Toulouse blind to the analysis of the Epileptogenic Zone (EZ), irritative and propagation zones and on all micro- and macro contacts, to the participating centre and to the period of recording. The results of the fast-ripple assessment will be provided to the clinicians on time for the MEM. They will incorporate this information along other usual clinical information gathered during the SEEG to reach a conclusion regarding the possibility of a neurosurgery. No analysis of the fast-ripples will be performed in the other group of patients with standard electrodes only. In this group, the conclusion regarding the possibility of a neurosurgery will thus be done during the MEM with the standard clinical information gathered during the SEEG only. Following epilepsy surgery, the typical follow-up performed in routine in all participating centres includes a clinical evaluation one year after surgery, during which Engel class is assessed.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Fast-ripples
  • Epilepsy
  • Neurosurgery
  • Hybrid electrodes
  • MICRODEEP® MME hybrid electrodes
  • StereoEEG
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient suffering from drug-resistant focal epilepsy (DRFE), as defined by the International League Against Epilepsy, undergoing SEEG, the indication of which was selected during a multidisciplinary epilepsy meeting
  • Patient who has given written to allow the study data collection procedures
  • Patient covered by the French healthcare system.

Exclusion criteria

Exclusion Criteria:

  • Patients under juridical protection (authorship, curators or safeguarding of justice).
  • Patient deprived of liberty by a judicial or administrative decision
  • Patient with a cardiac defibrillator
  • Patient in exclusion period of another study.
  • No other non-inclusion criteria since the study will only be proposed to patients who already meet the criteria for a SEEG
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
440 participants (estimated)

Study arms

  • Experimental
    Arm with fast-ripples information

    Patients for whom 4-6 usual clinical macro-electrodes will be replaced by hybrid micro-macro electrodes and for whom fast-ripples will be assessed

    Device: DIXI Medical Microdeep® Micro- Macro Depth electrodes

  • Active comparator
    Arm without fast-ripples information

    Patients who will undergo an SEEG with the usual electrodes and for whom fast-ripples will not be assessed.

    Device: Standard electrodes

Interventions

  • DeviceDIXI Medical Microdeep® Micro- Macro Depth electrodes

    It is a deep intracerebral electrode used in the pre-surgical diagnosis of certain drug-resistant epilepsies. It consists of micro- and macro-contacts and is designed for Stereo-ElectroEncephalography (SEEG) recording via the macro-contacts or micro-contacts and brief stimulation via the macro-contacts.

  • DeviceStandard electrodes

    Standard electrodes used usually during the SEEG

06

What researchers measure

Primary outcomes

  1. Contribution of fast-ripples information on freedom seizures

    Proportion of patients with Engel class I after one-year post-surgery in the group of patients with information of fast-ripples compared to patients without.

    Time frame: 12 months after epilepsy surgery

Secondary outcomes

  1. Contribution of fast-ripples information on improvement of epilepsy

    Proportion of patients with Engel classes I to III one-year post-surgery of patients with information of fast-ripples compared to patients without.

    Time frame: 12 months after epilepsy surgery

  2. Contribution of fast-ripples information on patients addressed to neurosurgery

    Proportion of patients operated for their epilepsy in the group of patients with information of fast-ripples compared to patients without.

    Time frame: 12 months after epilepsy surgery

  3. Adverse effects related to Stereo-electroencephalography

    Quantitative and qualitative description of adverse effects related to the Stereo-electroencephalography (SEEG) in the group of patients with information of fast-ripples compared to patients without.

    Time frame: Day 0 (SEEG visit)

  4. Adverse effects of epilepsy surgery

    Quantitative and qualitative description of adverse effects related to epilepsy surgery in the group of patients with information of fast-ripples compared to patients without.

    Time frame: 6 months after surgical decision

  5. Adverse effects of hybrid electrodes

    Quantitative and qualitative description of adverse effects related to the hybrid electrodes.

    Time frame: Day 0 (SEEG visit)

  6. Post-operative neurological deficit

    Number of patients suffering from disabling post-operative neurological deficit, anxiety or depression in the group of patients with information of fast-ripples versus patients without

    Time frame: 12 months after epilepsy surgery

  7. Evolution of quality of life using the score of Quality of life Epilepsy Inventory Epilepsy Inventory

    Delta of quality of life using the score of Quality of life Epilepsy Inventory (QOLIE-31) between baseline and 12 months related to epilepsy surgery in the group of patients with information of fast-ripples compared to patients without. QOLIE-31 is a 31-item questionnaire with different proposal scores. The maximal total score is 100 : the higher the score, the better the quality of life

    Time frame: 12 months after epilepsy surgery

  8. Level of satisfaction

    Mean of level of satisfaction with the outcome of epilepsy surgery assessed using the Evaluation of changes in daily life after epilepsy surgery (EVOCQUE) self-questionnaire, 12 months after surgery, related to epilepsy surgery in the group of patients with information of fast-ripples compared to patients without. EVOCQUE is a self-questionnaire with ten different questions and proposal scores.

    Time frame: 12 months after epilepsy surgery

  9. Recording of fast-ripples

    Number of fast-ripples recorded on the hybrid electrodes, on the one hand on the micro- contacts and on the other hand on the adjacent macro-contacts of the same hybrid electrode.

    Time frame: Day 0 (SEEG visit)

  10. Distribution of the fast-ripples

    Number of fast-ripples in the Epileptogenic Zone, Irritative Zone and healthy zone

    Time frame: Day 0 (SEEG visit)

  11. Number of fast-ripples recorded according to the period

    Number of fast-ripples recorded during one period of sleep, an equivalent period of nap and an equivalent period of sitcom watching.

    Time frame: Day 0 (SEEG visit)

  12. Contribution of using an Epileptogenicity Index

    Proportion of patients in Engel class I at one year after surgery among those whose epileptogenic zone was evaluated using an Epileptogenicity Index vs those whose epileptogenic zone was not evaluated using an Epileptogenicity Index in the group of patients with FR information and in the group of patients without FR information.

    Time frame: 12 months after epilepsy surgery

  13. Impact of RF-TC (Radiofrequency- Thermocoagulation) by SEEG on epilepsy at 4 months

    Proportion of seizure-free patients at 4 and 10 months post- SEEG (visits 3 and 4), among patients who underwent SEEG based RF-TC in the group of patients with FR information and in the group of patients without FR information.

    Time frame: Visit 3 : 4 months post-SEEG

  14. Impact of RF-TC (Radiofrequency- Thermocoagulation) by SEEG on epilepsy at 10 months

    Proportion of seizure-free patients at 10 months post- SEEG (visit 4), among patients who underwent SEEG based RF-TC in the group of patients with FR information and in the group of patients without FR information.

    Time frame: Visit 4 : 10 months post-SEEG

07

Study locations

12 of 12 sites recruiting
08

References and documents

Publications

  • Despouy E, Curot J, Reddy L, Nowak LG, Deudon M, Sol JC, Lotterie JA, Denuelle M, Maziz A, Bergaud C, Thorpe SJ, Valton L, Barbeau EJ. Recording local field potential and neuronal activity with tetrodes in epileptic patients. J Neurosci Methods. 2020 Jul 15;341:108759. doi: 10.1016/j.jneumeth.2020.108759. Epub 2020 May 7. PubMed 32389603 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Apr 2030, 75 months after the start.

Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's planned 75 months is above that.

Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 27, 2023
StartActual
Jan 19, 2024
Primary completionEst.
Apr 2030
CompletionEst.
Apr 2030
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. Fondation Adolphe de Rothschild is now Recruiting
Show site
  • Hôpital Pitié Salpêtrière · Paris, France
Oct 21, 2026
Eligibility
1 exclusion criterion removed
What changed in the criteria
Exclusion criteria
  • RemovedThermocoagulation planned on one of the potential hybrid electrodes .
Oct 21, 2026
Secondary outcomes
3 added
What changed in the outcomes
  • AddedContribution of using an Epileptogenicity IndexTime frame: 12 months after epilepsy surgery
  • AddedImpact of RF-TC (Radiofrequency- Thermocoagulation) by SEEG on epilepsy at 4 monthsTime frame: Visit 3 : 4 months post-SEEG
  • AddedImpact of RF-TC (Radiofrequency- Thermocoagulation) by SEEG on epilepsy at 10 monthsTime frame: Visit 4 : 10 months post-SEEG
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    1 site added. Fondation Adolphe de Rothschild is now Recruiting
    Show site
    • Hôpital Pitié Salpêtrière · Paris, France
    Eligibility 1 exclusion criterion removed
    What changed in the criteria
    Exclusion criteria
    • RemovedThermocoagulation planned on one of the potential hybrid electrodes .
    Secondary outcomes 3 added
    What changed in the outcomes
    • AddedContribution of using an Epileptogenicity IndexTime frame: 12 months after epilepsy surgery
    • AddedImpact of RF-TC (Radiofrequency- Thermocoagulation) by SEEG on epilepsy at 4 monthsTime frame: Visit 3 : 4 months post-SEEG
    • AddedImpact of RF-TC (Radiofrequency- Thermocoagulation) by SEEG on epilepsy at 10 monthsTime frame: Visit 4 : 10 months post-SEEG
    + 4 other changes: verification date, oversight details, description and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06105645
Collaborators
Centre de recherche Cerveau et Cognition (CERCO), Dixi Medical
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Jan 19, 2024
Primary completion
Apr 2030 (estimated)
Completion
Apr 2030 (estimated)
Last update
Oct 21, 2026

Study contacts

Luc VALTON, MD
Contact
valton.l@chu-toulouse.fr
0561775608 ext. +33
Yoan HERADES
Contact
yoan.herades@inserm.fr
Luc VALTON, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion